Press Releases
InspireMD to Announce First Quarter 2025 Financial Results
Miami, FL — April 25, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will… Read More
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Miami, Florida — April 8, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to 11 new non-executive employees in the aggregate amount of 299,398 shares of restricted stock… Read More
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
Miami, Florida — March 26, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time /… Read More
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
— Management to host investor conference call today, March 12th, at 8:30am ET — Miami, FL — March 12, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full… Read More
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
Miami, FL — February 26, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the… Read More
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Miami, Florida — February 25, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to six new non-executive employees in the aggregate amount of 138,442 shares of restricted stock… Read More
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
Toledo, Ohio and Miami, Florida — February 13, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing… Read More
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Miami, Florida — February 4, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD’s… Read More
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Miami, Florida — January 21, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to nine new non-executive employees in the aggregate amount of 372,135 shares of restricted stock outside of… Read More